Featured Research

from universities, journals, and other organizations

New medication shows promise in treating common skin disease

Date:
July 9, 2014
Source:
University of Rochester Medical Center
Summary:
An investigational medication shows promise in treating eczema or atopic dermatitis, the most common skin disorder, according to a study. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead author.

An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis, according to a study published July 9 in the New England Journal of Medicine. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead author Lisa A. Beck, M.D., professor of Dermatology and Medicine at the University of Rochester Medical Center.

The drug, dupilumab, blocks the action of two proteins involved in inflammation, interleukin-4 and interleukin-13, which play a key role in atopic dermatitis (AD). AD is a common skin disease with troubling signs that include severely dry skin, red lesions that may crust or ooze, skin thickening, and symptoms of intense itching that may lead to skin wounds, infections and sleep disturbance.

Moderate-to-severe AD is a more chronic version of the disease that typically has more systemic features and is seen in up to 3 percent of adults with the disease. AD can impact a person's ability to lead a full and active life. In addition, people with AD are more likely to have asthma and other allergic disorders such as hay fever. Current treatments for AD include topical and oral steroids as well as phototherapy, but their effectiveness is limited or the side effects associated with their chronic use are significant.

"We are encouraged by the consistent findings across these studies, which show that patients treated with dupilumab had a marked improvement in disease activity and itch," Beck said. "At this point, dupilumab appears to be remarkably effective for adults with severe AD, although larger studies are needed to confirm its safety and efficacy."

Dupilumab is administered as a skin injection, and has shown promise in both Phase I and Phase II studies. Participants in a 12-week Phase II study showed a 74 percent reduction in the Eczema Area Severity Index, a tool used to measure the severity of a patient's condition, compared to only 23 percent in the placebo group. The majority of patients in the group receiving dupilumab experienced significant reductions in itch.

The study's findings set the stage for Phase III clinical trials of dupilumab, to confirm its effectiveness, monitor side effects, and compare it to commonly used treatments.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lisa A. Beck, Diamant Thaηi, Jennifer D. Hamilton, Neil M. Graham, Thomas Bieber, Ross Rocklin, Jeffrey E. Ming, Haobo Ren, Richard Kao, Eric Simpson, Marius Ardeleanu, Steven P. Weinstein, Gianluca Pirozzi, Emma Guttman-Yassky, Mayte Suαrez-Fariρas, Melissa D. Hager, Neil Stahl, George D. Yancopoulos, Allen R. Radin. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine, 2014; 371 (2): 130 DOI: 10.1056/NEJMoa1314768

Cite This Page:

University of Rochester Medical Center. "New medication shows promise in treating common skin disease." ScienceDaily. ScienceDaily, 9 July 2014. <www.sciencedaily.com/releases/2014/07/140709182238.htm>.
University of Rochester Medical Center. (2014, July 9). New medication shows promise in treating common skin disease. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2014/07/140709182238.htm
University of Rochester Medical Center. "New medication shows promise in treating common skin disease." ScienceDaily. www.sciencedaily.com/releases/2014/07/140709182238.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins